Shares of Metsera Inc. (MTSR) have gained 6.8% over the past four weeks to close the last trading session at $35.32, but ...

MetseraMTSR got a positive adjustment to its Relative Strength (RS) Rating, from 88 to 93.Please watch the video at Investors ...

Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

Metsera is also joining its metabolic medicines peers who are developing oral GLP-1 drugs. The biotech’s candidate is MET-224o, an ultra-long acting GLP-1 receptor agonist made with technology ...

Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today anno Metsera Secures $215 Million Series B ...

--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its ...

Metsera, Inc., a clinical-stage biopharmaceutical company focused on treating obesity and metabolic diseases, announced its first quarter 2025 financial results, highlighting significant progress ...

Investment Overview - Metsera Latest To Join Obesity Market Challengers. Obesity is forecast by some analysts to become a >$200bn market, with up to 16 new drugs on the market by 2031. Eli Lilly ...

Metsera said its drug’s half-life of 19 days supports once-monthly dosing. That would be an advantage over the once-weekly dosing of the GLP-1 drugs currently available and the clinical-stage ...

Metsera, the obesity-focused biotech, said this morning that its drug candidate targeting the amylin hormone showed marked efficacy in an early trial and the potential to have longer-lasting ...

Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact: Jono Emmett ...